CA2064194A1 - Produits de conjugaison entre un lipide a et un vecteur immunogene et leur utilisation comme vaccin - Google Patents

Produits de conjugaison entre un lipide a et un vecteur immunogene et leur utilisation comme vaccin

Info

Publication number
CA2064194A1
CA2064194A1 CA002064194A CA2064194A CA2064194A1 CA 2064194 A1 CA2064194 A1 CA 2064194A1 CA 002064194 A CA002064194 A CA 002064194A CA 2064194 A CA2064194 A CA 2064194A CA 2064194 A1 CA2064194 A1 CA 2064194A1
Authority
CA
Canada
Prior art keywords
lipid
analog
conjugate
acyl groups
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002064194A
Other languages
English (en)
Inventor
Nelson Teng
Jerald Sadoff
Apurba K. Bhattacharjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Univax Biologics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2064194A1 publication Critical patent/CA2064194A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002064194A 1989-07-27 1990-07-20 Produits de conjugaison entre un lipide a et un vecteur immunogene et leur utilisation comme vaccin Abandoned CA2064194A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38586089A 1989-07-27 1989-07-27
US385,860 1989-07-27
US48789890A 1990-03-06 1990-03-06
US487,898 1990-03-06
US50255590A 1990-04-02 1990-04-02
US502,555 1990-04-02

Publications (1)

Publication Number Publication Date
CA2064194A1 true CA2064194A1 (fr) 1991-01-28

Family

ID=27409738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002064194A Abandoned CA2064194A1 (fr) 1989-07-27 1990-07-20 Produits de conjugaison entre un lipide a et un vecteur immunogene et leur utilisation comme vaccin

Country Status (5)

Country Link
EP (1) EP0484403A4 (fr)
JP (1) JPH04507244A (fr)
AU (1) AU651319B2 (fr)
CA (1) CA2064194A1 (fr)
WO (1) WO1991001750A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
DK0570682T3 (da) * 1992-05-07 1998-02-16 American Cyanamid Co Syntetiske lipid-A-glycoconjugat-antigener til anvendelse i vacciner
JP4860039B2 (ja) 1998-05-19 2012-01-25 リサーチ ディベロップメント ファンデーション トリテルペン組成物及びその使用法
EP1377320B1 (fr) 2001-04-04 2008-10-01 Nordic Vaccine Technology A/S Complexes de liaison de polynucleotides comprenant des sterols et des saponines
AU2003289493A1 (en) * 2002-12-24 2004-07-22 Mochizuki, Takashi Lipid a analogues having glucose as the right sugar
JP6374387B2 (ja) * 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224788A1 (de) * 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal Traegergebundenes immunogenes material
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
JPS63307897A (ja) * 1987-06-09 1988-12-15 Toho Yakuhin Kogyo Kk リピドａ単糖類縁体と硫黄含有ペプチドグリカン類縁体とを結合させた両親媒性化合物

Also Published As

Publication number Publication date
EP0484403A1 (fr) 1992-05-13
AU651319B2 (en) 1994-07-21
EP0484403A4 (en) 1993-03-17
WO1991001750A1 (fr) 1991-02-21
JPH04507244A (ja) 1992-12-17
AU6079590A (en) 1991-03-11

Similar Documents

Publication Publication Date Title
US5977081A (en) Triterpene saponin analogs having adjuvant and immunostimulatory activity
JP3717511B2 (ja) サポニン−抗原複合物とその用途
CA2064194A1 (fr) Produits de conjugaison entre un lipide a et un vecteur immunogene et leur utilisation comme vaccin
US11420993B2 (en) Semi-synthetic meningococcal conjugate vaccine
CA2128212A1 (fr) Vaccin conjugue lps-toxine du cholera detoxifie pour la prevention du cholera
EP1212334B1 (fr) Oligosaccharides derives de ribose-ribitol-phosphate et vaccins les contenant
JP6622804B2 (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン
EP0575517A1 (fr) Conjugues d'analogues de lipides a/support immunogene, emploi de ces composes comme vaccins et gammaglobulines hyperimmunes polyvalentes
EP1000076A1 (fr) VACCIN CONJUGUE HEXADECASACCHARIDE-PROTEINE CONTRE $i(SHIGELLA DYSENTERIAE) DE TYPE 1
US8716469B2 (en) Synthetic oligosaccharides for Moraxella vaccine
JP3369555B2 (ja) 薬剤および他の作用剤を標的へ向かわせるレセプター複合体
JPH0641200A (ja) 合成脂質ａ糖複合体抗原
KR830002059B1 (ko) 멀아밀-펲타이드형태인 신규 화합물의 제조방법
EP3000820A1 (fr) Vaccins contre le streptococcus pneumoniae de sérotype 8
MXPA99010675A (en) Triterpene saponin analogs having adjuvant and immunostimulatory activity

Legal Events

Date Code Title Description
FZDE Dead